Relationship between Bacillus Calmette Guerin Vaccination Policy and Coronavirus Disease-2019 (COVID-19) Incidence
Bacillus Calmette Guerin (BCG) was designed for protecting children against tuberculosis. Also, it can protect against other infectious diseases through the induction of trained immunity. Due to its heterologous protective effects, the BCG vaccine has been proposed as atreatment option for coronavirus disease-2019 (COVID-19). Epidemiological studies have found that countries without BCG vaccination policy have experienced higher mortality rates related toCOVID-19 infection than those with BCG vaccination policy. However, there are some confounding factors such as age, population intensity, immigration, the pandemic phase, and data accuracy that may affect these results. Therefore, this hypothesis should be evaluated by clinical trial studies. Large-scale clinical trials are in progress to investigate ifthe BCG vaccine could be used as a useful tool for protection against COVID-19 infection.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
---|---|
Enthalten in: |
Iranian journal of allergy, asthma, and immunology - 20(2021), 1 vom: 11. Feb., Seite 106-113 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Alyasin, Soheila [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Completed 10.03.2021 Date Revised 10.03.2021 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.18502/ijaai.v20i1.5417 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM321975316 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM321975316 | ||
003 | DE-627 | ||
005 | 20231225181039.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.18502/ijaai.v20i1.5417 |2 doi | |
028 | 5 | 2 | |a pubmed24n1073.xml |
035 | |a (DE-627)NLM321975316 | ||
035 | |a (NLM)33639625 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Alyasin, Soheila |e verfasserin |4 aut | |
245 | 1 | 0 | |a Relationship between Bacillus Calmette Guerin Vaccination Policy and Coronavirus Disease-2019 (COVID-19) Incidence |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 10.03.2021 | ||
500 | |a Date Revised 10.03.2021 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Bacillus Calmette Guerin (BCG) was designed for protecting children against tuberculosis. Also, it can protect against other infectious diseases through the induction of trained immunity. Due to its heterologous protective effects, the BCG vaccine has been proposed as atreatment option for coronavirus disease-2019 (COVID-19). Epidemiological studies have found that countries without BCG vaccination policy have experienced higher mortality rates related toCOVID-19 infection than those with BCG vaccination policy. However, there are some confounding factors such as age, population intensity, immigration, the pandemic phase, and data accuracy that may affect these results. Therefore, this hypothesis should be evaluated by clinical trial studies. Large-scale clinical trials are in progress to investigate ifthe BCG vaccine could be used as a useful tool for protection against COVID-19 infection | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a Mycobacterium bovis | |
650 | 7 | |a BCG Vaccine |2 NLM | |
700 | 1 | |a Kanannejad, Zahra |e verfasserin |4 aut | |
700 | 1 | |a Esmaeilzadeh, Hossein |e verfasserin |4 aut | |
700 | 1 | |a Nabavizadeh, Hesamedin |e verfasserin |4 aut | |
700 | 1 | |a Ghatee, Mohammad Amin |e verfasserin |4 aut | |
700 | 1 | |a Amin, Reza |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Iranian journal of allergy, asthma, and immunology |d 2003 |g 20(2021), 1 vom: 11. Feb., Seite 106-113 |w (DE-627)NLM167826980 |x 1735-5249 |7 nnns |
773 | 1 | 8 | |g volume:20 |g year:2021 |g number:1 |g day:11 |g month:02 |g pages:106-113 |
856 | 4 | 0 | |u http://dx.doi.org/10.18502/ijaai.v20i1.5417 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 20 |j 2021 |e 1 |b 11 |c 02 |h 106-113 |